Century Therapeutics
IPSC
65 hedge funds and large institutions have $12.6M invested in Century Therapeutics in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 15 increasing their positions, 21 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 70 → 65 (-5)
8.11% less ownership
Funds ownership: 34.36% → 26.25% (-8.1%)
10% less capital invested
Capital invested by funds: $14.1M → $12.6M (-$1.44M)
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
29% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$449K |
| 2 |
Millennium Management
New York
|
+$436K |
| 3 |
Two Sigma Investments
New York
|
+$261K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$250K |
| 5 |
Jane Street
New York
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$1.19M |
| 2 |
BlackRock
New York
|
-$1.12M |
| 3 |
CC
Casdin Capital
New York
|
-$1.06M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$845K |
| 5 |
State Street
Boston,
Massachusetts
|
-$386K |
IPSC Hedge Fund Activity: Q2 2025 in Review
65 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q2 2025, worth a combined $12.6M — down 10% from $14.1M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of IPSC and 21 opened new positions — a net loss of 5 holders — while 21 trimmed existing stakes and 15 added.
The largest buyer was Renaissance Technologies, adding an estimated $449K. The largest seller was VR Adviser, exiting entirely with an estimated $1.19M sold.
- 65 institutional investors held Century Therapeutics (IPSC) as of Q2 2025, down from 70 in Q1 2025.
- Funds reported $12.6M of Century Therapeutics stock for Q2 2025, down 10% quarter-over-quarter.
- 21 funds opened new Century Therapeutics positions in Q2 2025 and 26 closed out, a net change of -5 holders.
- The largest Century Therapeutics buyer in Q2 2025 was Renaissance Technologies, an estimated $449K added.
- The largest Century Therapeutics seller in Q2 2025 was VR Adviser, an estimated $1.19M sold.
Based on aggregated 13F filings for Q2 2025.